Online ISSN: 1949-2553
www.oncotarget.com
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

LEARN MORE ABOUT ONCOTARGET

Iron Chelators in Cancer Treatment

Trending

February 9, 2022
In a review paper published in Oncotarget in 2021, researchers discuss the impact of iron chelation on cancer cell survival and the underlying mechanisms of action. continue reading »

Behind the Study: Oncogenic Transformation and Iron Chelation

Oncotarget

February 7, 2022
Drs. Stephany Veuger and Gina Abdelaal from Northumbria University describe their 2021 review paper published by Oncotarget, entitled, "Reversing oncogenic transformation with iron chelation." continue reading »

Trending With Impact: What Causes Chemo Brain?

Oncotarget

January 27, 2022
Researchers investigated potential therapeutic culprits of “chemo brain” in a trending new paper published by Oncotarget. continue reading »

Prognostic Markers Identified in Ultra-Rare Adrenal Cancer

Oncotarget

January 26, 2022
Researchers demonstrated the overexpression of the protein APOBEC3B in adrenocortical carcinoma. They also identified the transcription factor, known as GATA3, that directly regulates APOBEC3B. continue reading »

Behind the Study: Prognostic Markers in Adrenocortical Carcinoma

Oncotarget

January 24, 2022
Dr. Monica Varun Tyagi discusses the research paper she co-authored that was published by Oncotarget, entitled, "GATA3 and APOBEC3B are prognostic markers in adrenocortical carcinoma and APOBEC3B is directly transcriptionally regulated by GATA3." continue reading »